Last reviewed · How we verify
Amiodarone hydrochloride tablet
At a glance
| Generic name | Amiodarone hydrochloride tablet |
|---|---|
| Also known as | Early-Amiodarone Protocol |
| Sponsor | Shanghai Chest Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Bioequivalence Study of Dronedarone Hydrochloride Tablets in Healthy Subjects Under Fasting Conditions (NA)
- Bioequivalence Study of Dronedarone Hydrochloride Tablets (NA)
- Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence (PHASE4)
- Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects (PHASE1)
- Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation (PHASE4)
- Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation (NA)
- Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amiodarone hydrochloride tablet CI brief — competitive landscape report
- Amiodarone hydrochloride tablet updates RSS · CI watch RSS
- Shanghai Chest Hospital portfolio CI